Recent studies have shown that at least 20% of the animal cell cultures currently in use in the US are contaminated by either microorganisms or other cell lines! This three part live, on-line seminar series will review the scope of this major problem and examine some of its causes and techniques for avoiding it. It will also explore some key, easy to employ strategies for preventing these losses by careful culture management.
Learn how to deliver integrated health and social care with big data and interoperability.
The Caldicott 2 report highlighted the practical difficulties that surround the sharing of service user data, especially when it’s not being used for direct care. Yet you still need to utilise big data and data sharing to comply with government policies aimed at providing better care.
Join us for this half-day executive briefing where experts from NHS England,Dell Healthcare will provide practical insights on how to enable interoperability and the use of business intelligence to better serve your communities.
We’ll show you how your healthcare data can help gain actionable insights, avoid unseen risks and discover missed opportunities using real-world examples.
Get insights on how to:
•Integrate data from different sources (such as the local authority and NHS commissioners)
•Create healthier communities, improve outcomes and lower healthcare costs through the innovative use of data analysis to predict and prevent ill-health
•Improve the patient engagement experience through seamless
•Ensure a more timely exchange of data to meet regulatory
•Create a cloud-based repository for data that can be accessed
from multiple locations and via different applications
In this webinar, learn about the new capabilities in the Informatica PowerCenter 10 editions and how they will increase your development agility.
Through the eyes and daily routine of typical developers and business analysts you will discover how this new release:
. Enhances the collaboration between IT developers and business analysts
. Delivers more powerful visualization for data profiling
. Delivers a new monitoring dashboard to view service health and system usage
. Increases your productivity with up to 50X faster data lineage rendering
. Enhances your project reach with new connectors and real time capabilities
. Includes new capabilities for parsing semi-structured and unstructured data
Watch this webinar to accelerate your deliver of data integration-based value to your organization.
Are you ready to transform healthcare with predictive analytics? Are you ready to turn Data into Insights and Insights into Practice? Predictive Analytics is about making better healthcare decisions. Is your organization Future Ready?
Are you ready to improve patient care, reduce risk and optimize resources? Are you ready for Predictive Analytics? Analytics is about making better business decisions. Do you understand what the customers want from you? Is your organization Future Ready?
Are you ready to make the most of your clinical technology investments? Dell Clinical application services connect clinical providers with critical patient information whenever and wherever it's needed. Like providing end to end applications and EHR solutions and services. We enhance the provider patient experience by ensuring that the right information is available at a moment's notice. Is your organization Future Ready?
Are you ready to engage with your patients? 40% of patients in US struggle with Chronic health conditions. The most improtant treatment protocol requires healthy lifestyle choices. But to take control and make these changes many patients need support. Dell Patient Engagement Solutions can provide that support. Is your organization Future Ready?
Richard Mendel MD, a Spinal Neurosurgeon from Tampa, Florida, gives a presentaion on the Basics of Stem Cells. Stem Cell Treatments are becoming more popular, and it benefit all to know the basics of this growing science.
Is your healthcare organization taking advantage of Cloud benefits? Cloud can help you simplify IT management and drive down the cost of IT operations. Dell secure healthcare cloud gives you access to industry leading security to reduce of burden of industry regulatory requirements and get the flexibility to adapt to the future. Is your organization Future Ready?
In recent days we have heard from CEO’s about the challenges they face when a breach occurs in determining what data has been lost. Was it sensitive customer data? If so, how many customers are impacted? Not knowing this information immediately causes further damage to customer confidence and significantly increases the cost of dealing with the breach itself.
In this webinar Informatica will introduce a new generation of Data Security Intelligence capabilities which will provide insight into exactly where company and customer sensitive data resides, how it is moving through the organization and what security measures are in place to protect it. We will also look at some of the proactive measures that can be quickly put in place at the database layer to prevent even authorized staff credentials from making unusual data requests, which are often the precursor to a costly breach.
We hope you can join us for what promises to be an informative and highly topical webinar.
Trinity Health is an 86-hospital system that recently completed a large merger with Catholic Health East. With demand for analytics across the enterprise growing faster than ever before, Trinity Health was in urgent need for gaining easy access to high quality, trusted data. One of the most pressing challenges for Trinity Health was to manage the inconsistent data from variety of applications as it was being moved in and out of different data warehouse systems. In order to extend their analytics platform beyond financials to include clinical, operational, and third party data, they needed to deliver connected, safe, and clean data. This meant adding data quality and master data management capabilities to their architecture. In addition to technology, Trinity Health relied on an enterprise-wide, comprehensive data governance and data investigation program to ensure the overall success of the analytics initiative.
This webinar will cover how the Trinity Health team achieved consensus for this program, collaborated with business and technical colleagues, and advanced data governance as a best practice to support advanced analytic initiatives.
During this webinar, you'll learn how to:
• Implement the best health information management technology
• Boost your agility to gain insight from healthcare data for better patient outcomes
• Facilitate patient data centricity for reduced costs with clean, safe data
The importance of genetic variations in drug transporters for drug disposition and response has been increasingly recognized in the past decade. The drug transporter organic anion transporting polypeptide 1B1 (OATP1B1) is genetically polymorphic and plays a major role in hepatic uptake of a variety of clinically important drugs. Predicting the pharmacokinetic effect of these genetic variants on the drug disposition is critical for understanding the inter-individual variations to drug efficacy and safety. Corning TransportoCells was introduced to support in vitro assessment of drug interaction with SLC transporter. Specially, the newly developed TransportoCells OATP1B1 SNPs, alongside with OATP1B1 wild type, offer an in vitro tool kit for studying the potential impact of genetic variants on drug PK.
This webinar will focus on the development and characterization of the newly available TransportoCells OATP1B1 genetic variants, three animal species Oatp family members and other drug transporters of emerging importance in drug development.
Primary human hepatocytes (PHHs) and other hepatic cell models possess several limitations. For instance, PHH’s large lot-to-lot variation requires qualification tests with each lot, resulting in high costs and increased lead time. Furthermore, other non-primary hepatic cells can have insufficient fold induction in some lots and conditions.
This presentation will introduce Corning® HepatoCells for ADME/Tox studies. Derived from primary human hepatocytes, Corning HepatoCells are a renewable, hepatocyte-like cell line that retains most of the physiological properties of their parental hepatocytes such as mature hepatocyte-like morphology and induction response to prototypical inducers of CYP3A4, 1A2, and 2B6. Characterization of Corning HepatoCells for ADME/Tox studies will be presented, along with data demonstrating how the model system can be used for prediction of clinical CYP induction.
Achieving your ADME/Tox testing goals requires experience, quality data, and proper alignment with regulatory guidance. Failure to meet these important requirements can put your drug discovery and pre-clinical goals at risk.
This presentation will provide an informative overview of how you can advance and reach your pre-clinical drug discovery goals. It will discuss the importance of core contract research capabilities, including enzyme induction, enzyme inhibition, and transporter interaction. In addition, we will review new capabilities and opportunities including CYP induction and SLC transporter assay services – all designed to align with regulatory agency guidance documents.
David Stresser is the Program Manager of Corning® Gentest℠ Contract Research Services at Corning Life Sciences since 2001, having held prior positions of Product Manager and Study Director since joining Corning in 1998. Prior to this, he was a post-doctoral associate in the laboratory of David Kupfer at the University of Massachusetts Medical School in Worcester, Massachusetts. He did his graduate work in the laboratory of David E. Williams at Oregon State University in Corvallis, Oregon receiving a Ph.D. in toxicology in 1994. Dr. Stresser has authored or co-authored 40 articles or book chapters in the field of drug metabolism and has been an invited speaker at various national and international meetings, pharmaceutical companies, and universities.
Join us on June 22nd for a special Corning-sponsored webinar presented by ATCC®.
Animal cell lines are important in vitro systems and tools for scientists in diverse disciplines such as basic cell biology, genetic mapping, gene expression and gene therapy. Cell line authentication and characterization are crucial in these activities, yet they are underappreciated by most research scientists. Over the years numerous cell lines have been shown to be misidentified due, in part, to poor techniques and inadequate verification of cell line authenticity. Technological advances have given rise to improved capabilities. Cell line authentication now requires a comprehensive strategy that employs several complementary technologies for systematic testing for morphology, microbial contaminations, cellular identity/cross-contamination as well as functionality. The validity of conclusions drawn from research data is dependent on consistent and unequivocal verification of cell line identity and function. It is estimated that the financial loss incurred by poorly characterized or misidentified cell lines is in the millions of dollars. An overview of the current technologies used to authenticate cell lines will be presented.
Dr. Yvonne A. Reid joined ATCC in 1980 and during the mid-1980’s her research focused on the use of DNA hypervariable probes for the intraspecies identification of cell lines. The evolution of this work has led to the implementation of routine screening of all human cell lines by STR analysis. She co-chaired the ATCC SDO committee on the Development Consensus Standard on the Authentication of Human Cell Lines: Standardization of STR profiling. Dr. Reid has more than 30 years of experience in cell biology, immunology and molecular biology. As Collection Scientist for the Cell Biology Program for over 10 years, she was responsible for acquisition of new animal cell lines and hybridomas into the Cell Biology General Collection.
This webinar will introduce the history, theory, basic techniques, and potential pit-falls of mammalian cell culture. It is designed for students and new lab technicians, as well as bench scientists interested in updating their techniques or knowledge in the field.
Topics to be discussed include:
• History and practical theories of cell culture and its impact on today’s science
• The requirements needed to set up a cell culture laboratory
• Challenges when performing mammalian cell culture and how to overcome them
About our Presenter:
Dr. Mark Rothenberg graduated from Emory University with his Ph.D. in Cell and Developmental Biology. Over the past 25 years, Mark has held positions in both academia and industry where he has developed an expertise in the areas of assay development and cell culture. He currently holds the position of Manager Scientific Training and Education with Corning Life Sciences.
There is a great interest in application of human mesenchymal stem cells (hMSCs) in cell therapy and tissue engineering due to their self-renewal, multi-lineage differentiation, immunomodulation, and trophic potential. One of the challenges faced in the clinical application of hMSCs is the need for efficient expansion of these cells in vitro without altering their capacity. Serum-free mammalian cell culture media, in particular, require optimization of the expansion protocols. Even subtle changes in routine handling can have a significant impact on the cells’ potential.
This seminar will cover the variables that can influence the desired regenerative and differentiation properties including medium selection, vessel surface treatment, impact of the cell source, and seeding density. We will also discuss how users can select the correct conditions for optimized growth and functionality.
Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has lead numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
As a key determinant of drug pharmacokinetics, transporter mediated drug-drug interaction has garnered significant attention from the pharmaceutical industry and regulatory authorities. Corning offers a comprehensive list of tools to support drug transporter studies and recently introduced Corning® TransportoCells™ products to support in vitro assessment of drug interaction with SLC transporters. This new model provides a convenient “thaw and go” cell-based model with robust activity and consistent performance. In this webinar, we will provide an overview of Corning TransportoCells products along with applications for in vitro-to-in vivo correlation. Validation data will also be presented for the newly available TransportoCells products, including OATP1A2, OATP2B1, PEPT1, PEPT2, and NTCP.
Dr. Na Li received her B.S degree in Biology from Fudan University, Shanghai, China, and her Ph.D. in Pharmacology from Dartmouth Medical School, Hanover, NH. Her major research focus is on drug transporters, including interspecies differences in hepatobiliary transporters, transporter quantification, and in vitro-to-in vivo extrapolation of drug pharmacokinetics. At Corning, Dr. Li contributes her expertise in in vitro drug transporter technology and its application in drug ADME.
Join us on January 28th for a special Corning-sponsored webinar presented by ATCC®.
The significance of 3D tissue modeling opens up new possibilities for the study of complex physiological processes in vitro. Advances in cell isolation, media development, substrates, and growth surfaces are leading to culture environments that provide better biological and functional properties than traditional 2D cell culture. These models may provide a more predictive analysis and result in a more streamlined process of drug discovery and development. In this webinar, we will discuss recent developments in 3D modeling using ATCC primary and hTERT immortalized cells with specialized Corning® permeable support culture systems in dermatologic and respiratory studies.
Dr. Yukari Tokuyama is a Field Application Scientist at ATCC. Prior to this role, she led the Stem Cell Product Development group and focused on products for human induced pluripotent stem cells and lineage specific differentiation. She earned her Ph.D. in Cell and Molecular Biology from the College of Medicine at the University of Cincinnati, where she studied the mechanism of genomic instability in cancer. She completed her post-doctoral training at the Oregon Health & Science University, Oregon National Primate Research Center, with a research focus on human and non-human primate stem cell biology.
Join us for a special Corning sponsored webinar presented by Promega Corporation.
Cells cultured in 3D model systems often acquire relatively large in vivo-like structures compared to the thickness of a 2D monolayer of cells grown on standard plastic plates. Multicellular 3D culture systems containing more than one cell type and exhibiting formation of a complex extracellular matrix represent a more physiologically relevant environment, yet provide a challenge for assay chemistries originally designed for measuring events from monolayers of cells. There is an unmet need for guidelines for design and verification of convenient and effective assays useful for larger 3D microtissues. Critical factors to consider for each model system and cell type include effective penetration of detection reagents and/or complete lysis of microtissue structures using combinations of detergent and physical disruption. We will present the approach used to verify performance of a bioluminescent ATP detection assay for measuring cell viability, a caspase assay for detecting apoptosis, and cell stress reporter assays to detect mechanisms leading to cytotoxicity. Recommendations for factors to consider when verifying performance of cell health assays on 3D culture models will be presented.
Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and has since held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also led efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Specialist, Cell Health involved in outreach educational training activities including validating assay systems applied to 3D cell culture models.
Primary cells can more closely mimic an in vivo-like state and generate more physiologically relevant data than immortalized cells. But unlike immortalized cells, primary cells have complex nutritional needs and require optimized growth conditions. In this webinar, you will learn:
•Proven techniques for isolating primary cells from tissues
•The importance of choosing the correct dissociation method
•Troubleshooting techniques for culturing healthier primary cells.
•Other topics to be discussed include:
-Choosing the optimal cell culture surface
-Selecting the optimal cell culture media
-Choosing the correct vessel for scaling-up
Angiogenesis is the process by which a new blood supply is established from pre-existing blood vessels. It is initiated by degradation of vessel basement membrane, endothelial cell proliferation, invasion, and directional migration towards chemoattractants, tube formation, and finally the establishment of a new vasculature.
We will discuss a portfolio of Corning products designed to investigate specific stages of angiogenesis through standardized and quantitative in vitro cell-based assays.
•HUVEC-2 Endothelial Cells—Widely studied endothelial cells that have been pre-screened for responsiveness to VEGF, a prototypic stimulator of angiogenesis
•ECMs and Chemoattractants—ECMs and key pro-angiogenic chemoattractants for optimal EC propagation, attachment, differentiation, and other key functions
•Endothelial Cell Invasion and Migration Assays—An enabling platform technology consisting of Corning® FluoroBlok™ microporous permeable supports coated with our unique extracellular matrix proteins for quantitation of endothelial cell migration and invasion
•Endothelia Cell Tube Formation Assay—A rapid assay system allowing direct screening of angiogenic compounds for their effects on endothelial cell tube formation
Paula Flaherty is a Technology Manager at Corning Life Sciences. Her team develops strategy and products focused on the modulation of in vitro cell behavior using extracellular matrix, media, vessel design, and growth factors. Prior to joining Corning Life Sciences, Paula studied retinal degeneration at the Berman-Gund Laboratory, Harvard Medical School in Boston, MA. She received her bachelor’s degree in Microbiology from the State University of New York and is an In Vitro Cell Biology Fellow, W. Alton Jones Cell Science Center in Lake Placid, NY.
Are you relying on biochemical and cell based in vitro assays in your research? In this webinar, Dr. Mark Rothenberg will share “insider” tips and tricks for enhancing your biochemical and cell-based assay performance.
Critical parameters for achieving success with these assays include understanding the assay dynamics, the instrumentation involved in reading the assay, and, in the case of cell-based assays, the environment in which the cells are grown impacts cellular physiology. Factors such as microplate geometry, density, surfaces, and instrumentation all play important roles in the success of the assay.
Learn how to:
•Select the correct microplate and its role in the success of the assay
•Choose the correct tip for your liquid handling needs
•Determine the correct instrumentation and settings to run your assay
In the past several decades, the usage of mammalian cell culture processes have allowed for better understanding of basic research and manufacturing of higher quality products compared to previous methods. Although much progress has been developed throughout the years, limitations and challenges during optimization of such processes in scale-up of mammalian cell cultures may be encountered.
This webinar will provide a simple guide and review of novel cell culture vessels and surface technologies that have enabled researchers to improve suspension and adherent mammalian cell culture scale-up. Additionally, this webinar will cover certain parameters to consider when scaling-up cells. Selecting the correct vessel and cell culture conditions will increase throughput without increasing laboratory space, incubator space, or time.
Extensive genomic sequencing efforts in recent years have provided detailed profiles of the somatic gene mutations that occur in a wide range of human cancers. In order to facilitate basic and translational cancer research, ATCC has designed and validated a number of genetic alteration cell panels targeting the key molecular pathways identified in these studies. To demonstrate suitability of the panels for high throughput screening, the EGFR panel was selected for evaluation using Corning® Epic® Technology, a label-free platform that uses optical biosensors for high sensitivity biochemical and cell-based assays.
Label-free dynamic mass redistribution (DMR) responses in whole cells provide phenotypic activity profiles which are readily amenable to evaluation of compound activity and pharmacology. DMR responses obtained using the EGFR cell panel showed that Epic Technology can be utilized to evaluate receptor responsiveness to ligands and successfully predict drug response. Furthermore, label-free phenotypic responses can provide profiles of cellular signaling pathways downstream of receptor activation that may identify alternative targets for drug screening in the cell panel. In summary, combining Epic Technology and the EGFR genetic alternation panel offers convenient tools to screen for ligands or biologics that directly target or affect EGFR receptor biology.
In this webinar, you will learn why partnering with Corning® GentestSM Contract Research will enable your company to reach goals faster. You will also learn about our latest service offerings, including new CYP induction and SLC transporter assay services - all designed to align with regulatory agency guidance documents. These services continue to strengthen our in vitro drug-drug interaction testing portfolio with a deep focus on enzyme inhibition, induction, and transport.
In vitro cell migration and invasion assays are frequently used as model systems for studying the directed movement of cells towards a chemoattractant stimulus, or to determine how a particular drug, growth factor or extra cellular matrix coating affects that movement. The classic method used to analyze this movement, the Boyden chamber, can be time-consuming, labor-intensive, and subjective.
An improved version of this technology was developed, Corning FluoroBlok. As cells migrate or invade through a fluorescence blocking membrane, they are detected using a bottom-reading microplate reader or inverted fluorescence microscope. Cells remaining in the upper chamber of the insert are shielded from detection, allowing for quantitation of cell numbers in this homogeneous assay system.
Recommended uses of the FluoroBlok system as well as recent improvements will be reviewed in this seminar.
The extracellular matrix (ECM) is a complex material that serves to stabilize tissues, promote cell attachment, and modulate cell functionality by specifically interacting with cell surface receptors. This material has been shown to play structural, biochemical and mechanical roles in the normal growth and differentiation of various cell types. Corning Matrigel Matrix, an ECM-based material isolated from EHS mouse tumors, is a widely used solubilized basement membrane preparation. Based on its physiological composition and functionality, Matrigel Matrix effectively models the physical interplay between diverse cell types and the ECM microenvironment in vivo.
Expansion of stem cells and some primary cells requires either animal-origin components in culture media or coating of the culture vessels with human or animal-derived extracellular matrix (ECM) protein. Growing concerns about introducing human and animal-derived pathogens into the culture necessitate the need for animal- free (xeno-free and human-origin components-free) culture environment. Herein, we present defined and synthetic surfaces for cell culture. Corning® PureCoat™ ECM Mimetic cultureware collagen I peptide and fibronectin peptide support culture of cell types requiring collagen I or fibronectin protein -coated surfaces. Corning Synthemax® surface consists of a vitronectin peptide and supports undifferentiated expansion of human pluripotent stem cells (hPSC) and neural progenitor cells (NPCs). ECM Mimetic and Synthemax cultureware are pre-coated, synthetic, animal-free, and room temperature stable. Synthemax-SC is available for self-coating.
We demonstrate expansion and functionality of several clinically relevant cell types including hPSCs, mesenchymal stem cells (MSCs), human keratinocytes (HKN), endothelial colony forming cells (ECFCs), NPCs and cell lines for biomanufacturing (CHO and Vero) on these surfaces. Corning Synthemax and ECM Mimetic cultureware are versatile surfaces compatible with multiple media for culture of various cell types providing a ready to use alternative to ECM protein coating where animal-free and defined conditions are desirable.
SLC transporter-mediated drug–drug interactions (DDI) can significantly impact the pharmacokinetics and safety profiles of drugs. The regulatory agencies (FDA/EMA) recent guidance documents recommend testing six SLC transporters for potential DDI: OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT2. The 2013 drug transporter white paper published by the International Transporter Consortium (ITC) identified additional drug transporters relevant to drug development, including the Multidrug and Toxin Extrusion SLC transporters: MATE1 and MATE2-K. The webinar will introduce a novel cell-based SLC transporter model system - the recently launched “Corning™ TransportoCells™” - for studying regulatory agency recommended SLC transporters. The new system provides a convenient “thaw and go”, high performing mammalian cell model which supports regulatory agency recommendations for evaluating transporter mediated drug-drug interactions in vitro. In this webinar, we will provide an overview of the product validation and applications for the TransportoCells™ transporter model system. Validation data will also be presented for the newly available MATE1 and MATE2-K Corning™ TransportoCells™.
Three-dimensional (3D) cell culture environments provide structural and biochemical cues for cellular differentiation and functionality. For specialized cell types such as primary cells, a two-dimensional growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, signal transduction, and tissue-specific gene expression. This webinar will highlight applications that rely on 3D materials and systems, including Corning ® Matrigel® Matrix (reconstituted basement membrane), Collagen Type I, Corning PuraMatrix™ Peptide Hydrogel, and permeable supports (cell culture inserts). To demonstrate the effectiveness of these environments, the biological and functional properties of a variety of cell types will be discussed.
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.